Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?

Colorectal cancer (CRC) ranks as the third most prevalent cancer globally and stands as the fourth leading cause of cancer-related fatalities in 2020. Survival rates for metastatic disease have slightly improved in recent decades, with clinical trials showing median overall survival of approximately...

Descripción completa

Detalles Bibliográficos
Autores: Moreta Moraleda, Cristina, Queralt, Cristina, Vendrell-Ayats, Carla, Forcales Fernàndez, Sonia-Vanina, Martínez Balibrea, Eva
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/208022
Acceso en línea:https://hdl.handle.net/2445/208022
Access Level:acceso abierto
Palabra clave:Marcadors bioquímics
Cromatina
Càncer colorectal
Epigenètica
Biochemical markers
Chromatin
Colorectal cancer
Epigenetics
id ES_8eb5a3eaf9b4cc14122be511beeef1d4
oai_identifier_str oai:recercat.cat:2445/208022
network_acronym_str ES
network_name_str España
repository_id_str
spelling Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?Moreta Moraleda, CristinaQueralt, CristinaVendrell-Ayats, CarlaForcales Fernàndez, Sonia-VaninaMartínez Balibrea, EvaMarcadors bioquímicsCromatinaCàncer colorectalEpigenèticaBiochemical markersChromatinColorectal cancerEpigeneticsColorectal cancer (CRC) ranks as the third most prevalent cancer globally and stands as the fourth leading cause of cancer-related fatalities in 2020. Survival rates for metastatic disease have slightly improved in recent decades, with clinical trials showing median overall survival of approximately 24-30 months. This progress can be attributed to the integration of chemotherapeutic treatments alongside targeted therapies and immunotherapy. Despite these modest improvements, the primary obstacle to successful treatment for advanced CRC lies in the development of chemoresistance, whether inherent or acquired, which remains the major cause of treatment failure. Epigenetics has emerged as a hallmark of cancer, contributing to master transcription regulation and genome stability maintenance. As a result, epigenetic factors are starting to appear as potential clinical biomarkers for diagnosis, prognosis, and prediction of treatment response in CRC.In recent years, numerous studies have investigated the influence of DNA methylation, histone modifications, and chromatin remodelers on responses to chemotherapeutic treatments. While there is accumulating evidence indicating their significant involvement in various types of cancers, the exact relationship between chromatin landscapes and treatment modulation in CRC remains elusive. This review aims to provide a comprehensive summary of the most pertinent and extensively researched epigenetic-associated mechanisms described between 2015 and 2022 and their potential usefulness as predictive biomarkers in the metastatic disease.Elsevier B.V.2024202420232024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion19 p.application/pdfhttps://hdl.handle.net/2445/208022Articles publicats en revistes (Patologia i Terapèutica Experimental)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1016/j.phrs.2023.106924Pharmacological Research, 2023, vol. 196, p. 106924https://doi.org/10.1016/j.phrs.2023.106924cc-by-nc (c) Moreta Moraleda, Cristina et al.; Elsevier B.V., 2023https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2080222026-05-29T05:05:01Z
dc.title.none.fl_str_mv Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?
title Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?
spellingShingle Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?
Moreta Moraleda, Cristina
Marcadors bioquímics
Cromatina
Càncer colorectal
Epigenètica
Biochemical markers
Chromatin
Colorectal cancer
Epigenetics
title_short Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?
title_full Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?
title_fullStr Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?
title_full_unstemmed Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?
title_sort Chromatin factors: Ready to roll as biomarkers in metastatic colorectal cancer?
dc.creator.none.fl_str_mv Moreta Moraleda, Cristina
Queralt, Cristina
Vendrell-Ayats, Carla
Forcales Fernàndez, Sonia-Vanina
Martínez Balibrea, Eva
author Moreta Moraleda, Cristina
author_facet Moreta Moraleda, Cristina
Queralt, Cristina
Vendrell-Ayats, Carla
Forcales Fernàndez, Sonia-Vanina
Martínez Balibrea, Eva
author_role author
author2 Queralt, Cristina
Vendrell-Ayats, Carla
Forcales Fernàndez, Sonia-Vanina
Martínez Balibrea, Eva
author2_role author
author
author
author
dc.subject.none.fl_str_mv Marcadors bioquímics
Cromatina
Càncer colorectal
Epigenètica
Biochemical markers
Chromatin
Colorectal cancer
Epigenetics
topic Marcadors bioquímics
Cromatina
Càncer colorectal
Epigenètica
Biochemical markers
Chromatin
Colorectal cancer
Epigenetics
description Colorectal cancer (CRC) ranks as the third most prevalent cancer globally and stands as the fourth leading cause of cancer-related fatalities in 2020. Survival rates for metastatic disease have slightly improved in recent decades, with clinical trials showing median overall survival of approximately 24-30 months. This progress can be attributed to the integration of chemotherapeutic treatments alongside targeted therapies and immunotherapy. Despite these modest improvements, the primary obstacle to successful treatment for advanced CRC lies in the development of chemoresistance, whether inherent or acquired, which remains the major cause of treatment failure. Epigenetics has emerged as a hallmark of cancer, contributing to master transcription regulation and genome stability maintenance. As a result, epigenetic factors are starting to appear as potential clinical biomarkers for diagnosis, prognosis, and prediction of treatment response in CRC.In recent years, numerous studies have investigated the influence of DNA methylation, histone modifications, and chromatin remodelers on responses to chemotherapeutic treatments. While there is accumulating evidence indicating their significant involvement in various types of cancers, the exact relationship between chromatin landscapes and treatment modulation in CRC remains elusive. This review aims to provide a comprehensive summary of the most pertinent and extensively researched epigenetic-associated mechanisms described between 2015 and 2022 and their potential usefulness as predictive biomarkers in the metastatic disease.
publishDate 2023
dc.date.none.fl_str_mv 2023
2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/208022
url https://hdl.handle.net/2445/208022
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1016/j.phrs.2023.106924
Pharmacological Research, 2023, vol. 196, p. 106924
https://doi.org/10.1016/j.phrs.2023.106924
dc.rights.none.fl_str_mv cc-by-nc (c) Moreta Moraleda, Cristina et al.; Elsevier B.V., 2023
https://creativecommons.org/licenses/by-nc/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc (c) Moreta Moraleda, Cristina et al.; Elsevier B.V., 2023
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 19 p.
application/pdf
dc.publisher.none.fl_str_mv Elsevier B.V.
publisher.none.fl_str_mv Elsevier B.V.
dc.source.none.fl_str_mv Articles publicats en revistes (Patologia i Terapèutica Experimental)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413151510888448
score 15,812429

Similares en LA Referencia